FDA Audit Preparation Checklist for Life Sciences

Understanding FDA Regulatory Inspections for NDAs

FDA regulatory inspections conducted in support of New Drug Applications (NDAs) assess whether a company’s facilities, processes, and quality systems operate in compliance with applicable regulatory requirements. These inspections focus on confirming that manufacturing and quality oversight consistently support product safety, quality, and reliability.

During an inspection, FDA investigators typically aim to:

• Verify compliance with current Good Manufacturing Practice (cGMP) regulations

• Review documentation, batch records, and data integrity practices

• Assess facility operations, equipment qualification, and maintenance controls

• Evaluate personnel training, competency, and procedural adherence

Thorough preparation is essential to reduce the likelihood of Form 483 observations, warning letters, or delays in product approval.

---

Key Steps to Ensure NDA Inspection Readiness

Conduct Internal Audits

Internal audits provide early visibility into compliance risks before regulatory inspection.

• Perform comprehensive reviews of manufacturing operations and quality systems

• Evaluate procedural execution against documented requirements

• Identify potential compliance gaps and operational risks

---

Perform Gap Analysis and Corrective Actions

A structured gap assessment helps align systems with FDA expectations.

• Review SOPs, validation programs, and quality documentation

• Compare current practices against regulatory requirements and guidance

• Implement corrective and preventive actions (CAPAs) to address identified gaps

---

Ensure Documentation Is Audit-Ready

Inspection outcomes often depend on documentation quality and traceability.

• Prepare batch records, laboratory documentation, and quality system records

• Maintain accurate, complete, and contemporaneous data

• Ensure records demonstrate clear compliance with cGMP standards

---

Staff Training and Mock Inspections

Inspection readiness depends on both systems and personnel preparedness.

• Train employees on inspection conduct and communication expectations

• Conduct mock inspections to simulate investigator interactions

• Reinforce roles, responsibilities, and escalation procedures

---

Develop a Structured Regulatory Strategy

Inspection preparation should align with broader regulatory planning.

• Align readiness activities with FDA guidance and NDA timelines

• Establish internal communication and response procedures

• Prepare structured follow-up processes for inspection outcomes

---

Why NDA Inspection Preparation Is Critical

Effective preparation for FDA NDA inspections helps organizations:

• Reduce the risk of regulatory observations and approval delays

• Strengthen documentation control and audit readiness

• Ensure staff confidence and consistency during inspections

• Improve overall compliance posture and operational performance

• Support more predictable NDA approval and market entry timelines

A structured, proactive approach to inspection readiness enables organizations to demonstrate sustained control rather than last-minute preparation, an approach regulators increasingly expect during NDA evaluations.